第39卷第3期2023年3月长春中医药大学学报JournalofChangchunUniversityofChineseMedicineVol.39No.3Mar.2023—315—DOI:10.13463/j.cnki.cczyy.2023.03.019替罗非班治疗急性缺血性脑卒中赵秋艳，朱雪莲，李碧，张璐，党旭良，乔飞（新疆生产建设兵团第四师医院神经内科，新疆伊犁835000）摘要：目的目的探讨替罗非班治疗急性缺血性脑卒中（AIS）的疗效及安全性。方法方法选择急性缺血性脑卒中患者300例，采取前瞻性、非随机对照分为替罗非班组、rt-PA组、常规治疗组，各100例。替罗非班组予替罗非班治疗，rt-PA组予溶栓治疗，常规治疗组予常规药物治疗，观察3组神经功能、日常生活能力和不良事件发生情况。结果结果替罗非班组治疗后24h、7d、30d、90d的mRS量表评分、NIHSS量表评分低于rt-PA组和常规治疗组（P＜0.05），日常生活评分高于rt-PA组和常规治疗组（P＜0.05）。mRS量表评分、NIHSS量表评分以及日常生活评分的组间、时间点及交互差异均有统计学意义（P＜0.05）。3组治疗后24h内症状性颅内出血率，治疗后90d内全因死亡率以及血小板计数降低发生情况比较无显著性差异（P＞0.05）。结论结论替罗非班治疗急性缺血性脑卒中效果良好，且不会增加不良事件发生，安全性较好。关键词：替罗非班；急性缺血性脑卒中；溶栓；神经功能中图分类号：R45文献标志码：A文章编号：2095-6258(2023)03-0315-04EffectandsafetyoftirofibaninthetreatmentofacuteischemicstrokeEffectandsafetyoftirofibaninthetreatmentofacuteischemicstrokeZHAOQiuyan,ZHUXuelian,LIBi,ZHANGLu,DANGXuliang,QIAOFei(DepartmentofNeurology,FourthDivisionHospitalofXinjiangProductionandConstructionCorps,Yili835000,China)Abstract:ObjectiveAbstract:ObjectiveToexploretheeffectandsafetyoftirofibaninthetreatmentofacuteischemicstroke(AIS).MethodsMethodsAtotalof300patientswithAISmeetingtheinclusioncriteriaintheneurologydepartmentoftheFourthDivisionHospitalwereenrolledbetweenJanuary2019andJune2021.Accordingtoaprospectiveandnon-randomizedcontrolmethod,theyweredividedintoatirofibangroup(tirofiban),anrt-PAgroup(thrombolysis)andaroutinetreatmentgroup(routinedrugs),with100casesineachgroup.Thenervefunction,activitiesofdailylivingandoccurrenceofadverseeventsinthethreegroupswereobserved.ResultsResultsAtthe24thhour,andonthe7th,30rd...
